MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in… May 11, 2022
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS Jan 12, 2022
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical… Nov 30, 2021
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease Oct 6, 2021